India's Strategic Role in the WHO Global Pandemic Agreement

#GS-2 #Governance & Social Justice #Current Events #Health #International #Global Pandemic Agreement #World Health Organization #PABS System

Key takeaways

The WHO Pandemic Agreement was adopted by 124 member states in 2025 to create a legally binding global response system for future health crises.
The main conflict involves the Pathogen Access and Benefit-Sharing (PABS) system, where developing nations demand guaranteed affordable vaccines in exchange for sharing virus sample data.
India needs this treaty to protect its pharmaceutical sector from foreign Active Pharmaceutical Ingredients (APIs) supply shocks while keeping access to advanced mRNA patent platforms.
India is leading negotiations by promoting its Global Initiative on Digital Health (GIDH) created during its 2023 G20 Presidency as an affordable tool for global disease tracking.

India recently presented official remarks at the United Nations High-Level Meeting (UN HLM) in New York regarding the Political Declaration for Pandemic Prevention, Preparedness, and Response (PPPR).
These official remarks strongly supported and reinforced the World Health Organization (WHO) led Global Pandemic Agreement.

The World Health Assembly adopted the WHO Pandemic Agreement in May 2025 as an international framework to strengthen global pandemic prevention, preparedness, and response.
This framework aims to ensure equitable access to vaccines, diagnostics, and medical treatments while improving disease surveillance and health system resilience.

The World Health Organization (WHO) negotiated this legally binding international agreement to avoid repeating the severe vaccine shortages and distribution unfairness seen during COVID-19.
A total of 124 member states formally adopted this global framework in 2025 with zero negative votes and 11 abstentions.
The Pathogen Access and Benefit-Sharing (PABS) system is a critical remaining annex that requires countries sharing pathogen data to receive guaranteed and affordable medical countermeasures.
A major global disagreement pits High-Income Countries against Low- and Middle-Income Countries regarding forced technology transfers and mandatory intellectual property waivers.

India makes most of the world's vaccines, but Western pharmaceutical companies still own the patents for advanced mRNA technologies.
Indian pharmaceutical companies rely heavily on foreign Active Pharmaceutical Ingredients (APIs), leaving local manufacturing vulnerable to international supply disruptions.
India can use its successful domestic digital health tools and laboratory networks as Digital Public Infrastructure (DPI) to build stronger diplomatic ties across the Global South.
A balanced treaty protects national sovereignty so that international One Health surveillance rules do not place heavy regulatory burdens on local farmers and health systems.

Rich nations want open access to viral sample data immediately, but they refuse to promise affordable medicines back to the source countries under PABS.
High-Income Countries want voluntary patent licensing agreements, while developing nations demand mandatory technology transfers during health emergencies.
Global monitoring rules for human and animal health create expensive infrastructure demands that developing countries cannot afford without external funding.
Some developed nations reject international oversight because they fear WHO emergency declarations will override their domestic policy decisions.

India defended two main principles at the UN HLM: guaranteed access to emergency medical supplies and complete respect for national policy independence.
India uses its Global Initiative on Digital Health (GIDH) platform from its 2023 G20 Presidency to provide affordable disease tracking systems globally.
India builds consensus between rich donor nations and developing countries through international coalitions like the 2026 Partners for Multilateralism group.
India uses global platforms like the UK-led H20 summit to keep equity for developing nations at the center of future health policy plans.

India should update its Biological Diversity Act and national patent rules to match global access and benefit-sharing standards under the Nagoya Protocol.
The government must expand Production Linked Incentive (PLI) schemes for Key Starting Materials (KSMs) to reduce import dependence for local vaccine makers.
India can set up regional vaccine manufacturing hubs in South Asia and Africa using bilateral aid and technical assistance.
India needs to create affordable One Health tracking toolkits that help developing nations monitor animal diseases without harming local livestock farming.

India is uniquely qualified to connect developed and developing nations because it is both a major medicine exporter and a leading voice for the Global South.
By promoting a fair pathogen-sharing system, India can protect its pharmaceutical supply chains while helping build a safer global health system.